Loading
Journal of AIDS and HIV Treatment
ISSN: 2688-7436
Commentary – HIV-Induced Extracranial Carotid Ectasia and Stroke
HIV is a known risk factor for both ischemic and hemorrhagic stroke. Even with the widespread use of antiretroviral therapy, stroke incidence is higher in patients with HIV compared to non-HIV control subjects.
J AIDS HIV Treat, 2021, Volume 3, Issue 2, p24-26 | DOI: 10.33696/AIDS.3.017Older Versus Younger Men Who Have Sex with Men: Awareness of and Potential Barriers to the Use of Pre-Exposure Prophylaxis (PrEP) Medication to Prevent the Transmission of HIV
Men who have sex with other men (MSM) comprise the single largest group of individuals contracting HIV in the United States, accounting for more than one-half of all new HIV diagnoses.
J AIDS HIV Treat, 2020, Volume 2, Issue 2, p42-50 | DOI: 10.33696/AIDS.2.006Use of Humanized Mouse Models for Studying HIV-1 Infection, Pathogenesis and Persistence
Different humanized mouse models have been introduced to enable HIV-1 research in vivo, which has been made possible by the development of immunodeficient mouse strains.
J AIDS HIV Treat, 2020, Volume 2, Issue 1, p23-29 | DOI: 10.33696/AIDS.2.003Development of an Ultrasensitive HIV-1 DNA Detection Assay Based on an Automated πCode End-Point PCR System
Currently, around 60-75% of the HIV positive patients in developed countries on anti-retroviral therapy (ART) have undetectable plasma viral load using current diagnostic PCR assays.
J AIDS HIV Treat, 2019, Volume 1, Issue 2, p69-88 | DOI: 10.33696/AIDS.1.010HIV-1 Treatment Failure among Population Taking Antiretroviral Therapy in Ethiopia
For more than 35 years, the world has grappled with an AIDS epidemic that has claimed an estimated 35.0 million [28.9 million-41.5 million] lives and at its peak threatened global stability and security.
J AIDS HIV Treat, 2019, Volume 1, Issue 2, p46-57 | DOI: 10.33696/AIDS.1.008Assessment of Attitudes toward HIV and AIDS among Undergraduate Students at a Historically Black University
HIV is no longer only a public health challenge, but also a global threat with a devastating negative impact that has claimed over 35 million lives globally. In 2017, about 36.9 million people live with HIV, and 1.8 million people becoming newly infected with the disease globally [1].
J AIDS HIV Treat, 2019, Volume 1, Issue 2, p25-32 | DOI: 10.33696/AIDS.1.006CCR5 Inhibitors and HIV-1 Infection
Cellular components are attractive targets for antiviral therapy because they do not mutate as readily as do viral proteins do [1-3]. The identification of CCR5 as an HIV-1 coreceptor [4-7], facilitated by the discovery of the antiviral activities of CCR5 ligand ?-chemokines [8], resulted in the development of new viral entry inhibitors to block CCR5 binding, including both- small molecules and CCR5 antibodies
J AIDS HIV Treat, 2019, Volume 1, Issue 1, p1-5 | DOI: 10.33696/AIDS.1.001Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.